Thanks Chels, it will be very interesting to read the MPS VI trial which is blinded and up against placebo. The numbers are larger there so that also will be good to see. Specially from a pain front, it really is the only viable option apart from NSAIDS which have many problems if used on a daily basis over a longer period of time.
I think there will be a big case once approved to start iPPS early in life for these guys...this also is why the Brazil study (MPS VI) is important as it breaks the cohort by age stratum as well.
research reports and media, page-3742
-
- There are more pages in this discussion • 687 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |